Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Labcorp Introduces Innovative Biomarker-Based Blood Test for Precision Health in Preeclampsia Management

NextEdge Admin

31 Jan 2024

2 min 21 sec

Labcorp has unveiled a groundbreaking FDA-cleared blood test designed for assessing and managing severe preeclampsia, a potentially life-threatening blood pressure disorder occurring during pregnancy and the postpartum period. Affecting 2-5% of pregnancies, preeclampsia poses significant risks to both maternal and neonatal health, and conventional diagnostic methods like blood pressure and proteinuria assessments often fall short in predicting severe outcomes.

Developed by Thermo Fisher Scientific and recognized as one of TIME Magazine’s Best Inventions of 2023, the new test measures two angiogenic biomarkers linked to preeclampsia: serum soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF). By analyzing the ratio of these biomarkers, along with other clinical assessments, the test aids clinicians in identifying pregnant patients at risk of progressing to severe preeclampsia within two weeks of testing.

Validated by the PRAECIS study involving over 1,000 pregnant women across 18 U.S. hospitals, the blood-based test is intended for singleton pregnancies between 23+0 and 34+6/7 weeks gestation. Positive results, indicated by an sFlt-1/PlGF ratio ≥ 40, prompt enhanced surveillance and accelerated care, allowing for proactive management before severe features manifest.

Labcorp’s collaboration with Thermo Fisher aligns with their commitment to advancing diagnostic capabilities, supporting healthcare providers with early and objective information for improved preeclampsia management. The test aims to contribute to better outcomes for both parents and newborns by offering comprehensive and advanced diagnostic solutions in line with Labcorp’s mission to enhance health and lives.